Endocrinology Medical News about HDL biosynthesis defect

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Identification of a novel human cellular HDL biosynthesis defect
European Heart Journal, 06/30/09

Rashid S et al. – Results indicate for the first time in humans that phospholipid and cholesterol efflux are 2 separate and distinct processes in cellular high-density lipoprotein (HDL) biosynthesis and that normal cellular phospholipid efflux is necessary for formation of larger {alpha}-HDL particles. Defective ABCA1 protein regulation results in a defect in phospholipid efflux, treatable with physiological oxysterols, a current therapeutic target that may serve to raise HDL levels in severe HDL deficiencies, pending further study.

Methods

Study of the cellular basis of a novel HDL-deficiency phenotype
Screen of 54 subjects of French Canadian ancestry with severe HDL deficiency
Exclusion of pts with mutations in genes currently associated with low HDL (ABCA1, LCAT, APOA-I, and SMPD1)

Results

Cellular phospholipid efflux impaired in HDL biosynthesis process but cholesterol efflux normal in 2 pts
On 2-dimensional gel electrophoresis analysis, the 2 impaired phospholipid efflux pts primarily defective in larger {alpha}-HDL subpopulations
In fibroblasts from affected subjects, oxysterol stimulation resulted in increased ABCA1 protein expression and normalized defective phospholipid efflux defect

<< Previous
Bone as an endocrine organ

Next >>
Influence of pre-hypertension on all-cause and cardiovascular...